中文(ZH) 立方制药：取得美阿沙坦钾片药品注册证书

立方药业获批高血压治疗药物

作者 PulseAugur 编辑部 · [1 个来源] · 2026-05-22 10:39

立方药业已获得中国国家药品监督管理局对其阿利吉仑美多沙酯钾片的批准，该药物适用于治疗成人原发性高血压。这标志着该公司在医药领域迈出了重要一步。此次批准涵盖了该药物的40毫克和80毫克两种剂量。 AI

排序理由公司收到监管机构的药品注册证。[lever_c_demoted from research: ic=1 ai=0.1]

AI 生成摘要 · Google Gemini · 来自 1 个来源。我们如何撰写摘要 →

本文如何被排名

Signal score: 0 / 100; Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket: Tool; 公司收到监管机构的药品注册证。[lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration: Single-source cluster; Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics: product, other; Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance: Low; Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness: 139 days old; Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。

36氪 (36Kr) TIER_1 中文(ZH) · 2026-05-22 10:39

Cube Pharmaceuticals：获得阿齐沙坦酯钾片药物注册证

36氪获悉，立方制药公告，公司收到国家药品监督管理局核准签发的美阿沙坦钾片（40mg、80mg）《药品注册证书》，该药品适用于治疗成人原发性高血压。